Case Report: Treatment response of SQSTM1–ALK fusion lung adenocarcinoma to multiple ALK inhibitors

ObjectivesThe echinoderm microtubule-associated protein-like 4 (EML4) gene and anaplastic lymphoma kinase (ALK) gene fusion is the most common ALK rearrangement in non-small-cell lung cancer (NSCLC). SQSTM1 (exon 5)–ALK (exon 20) fusion in patients with NSCLC was first identified in 2015. However, t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jincui Gu, Jing Zhang, Shaoli Li, Ziying Lin, Lixia Huang, Yanbin Zhou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-09-01
Edice:	Frontiers in Pharmacology
Témata:	lung adenocarcinoma SQSTM1–anaplastic lymphoma kinase fusion anaplastic lymphoma kinase inhibitors case report treatment
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1608080/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!